Global Glatiramer Market

Glatiramer Comprehensive Study by Type (Brand Medicine, Generic Drug), Application (Hospital, Pharmacy, Other), Route of Administration (Enteral Route, Parenteral Route), Intake Form (Alone, With Other Medications) Players and Region - Global Market Outlook to 2030

Glatiramer Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 3.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Glatiramer Market Scope
Glatiramer, also known as Copaxone, is an immunomodulator medication used to treat multiple sclerosis. In the United States, latiramer acetate is approved to reduce the frequency of relapses but not to slow the progression of disability. Copaxone (glatiramer acetate) is a combination of four amino acids (proteins) used to treat and prevent relapses of multiple sclerosis (MS). Copaxone will not cure MS, but it can make relapses occur less often.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledTeva (Israel), NATCO Pharma (India), Mylan (United States), Novartis (Switzerland) and HYBIO (China)
CAGR3.7%


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.

Teva (Israel), NATCO Pharma (India), Mylan (United States), Novartis (Switzerland) and HYBIO (China) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Glatiramer market by Type , by Application (Hospital, Pharmacy and Other) and Region with country level break-up.

On the basis of geography, the market of Glatiramer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In October 2022, Teva Pharmaceutical Industries partnered with Alvotech Holdings to develop and commercialize a biosimilar version of glatiramer acetate (Copaxone®) in certain territories.
In April 2023, Teva launched Glatiramer Acetate Injection 40mg/mL prefilled syringe, offering a new dosage option for patients with relapsing-remitting multiple sclerosis (RRMS).


Influencing Trend:
Emergence Of Multiple Sclerosis Treatment Options

Market Growth Drivers:
The Growing Geriatric Population Is Expected To Drive Growth Of The Market Over The Forecast Period.

Challenges:
High Cost of the Multiple Sclerosis Treatment

Restraints:
The Adverse Effect of the Treatment

Opportunities:
Innovative Drug Development Opening A New Horizon For multiple sclerosis

Key Target Audience
Multiple Sclerosis Treatment Providers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Brand Medicine
  • Generic Drug
By Application
  • Hospital
  • Pharmacy
  • Other
By Route of Administration
  • Enteral Route
  • Parenteral Route

By Intake Form
  • Alone
  • With Other Medications

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Growing Geriatric Population Is Expected To Drive Growth Of The Market Over The Forecast Period.
    • 3.3. Market Challenges
      • 3.3.1. High Cost of the Multiple Sclerosis Treatment
    • 3.4. Market Trends
      • 3.4.1. Emergence Of Multiple Sclerosis Treatment Options
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Glatiramer, by Type, Application, Route of Administration, Intake Form and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Glatiramer (Value)
      • 5.2.1. Global Glatiramer by: Type (Value)
        • 5.2.1.1. Brand Medicine
        • 5.2.1.2. Generic Drug
      • 5.2.2. Global Glatiramer by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Pharmacy
        • 5.2.2.3. Other
      • 5.2.3. Global Glatiramer by: Route of Administration (Value)
        • 5.2.3.1. Enteral Route
        • 5.2.3.2. Parenteral Route
      • 5.2.4. Global Glatiramer by: Intake Form (Value)
        • 5.2.4.1. Alone
        • 5.2.4.2. With Other Medications
      • 5.2.5. Global Glatiramer Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Glatiramer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. NATCO Pharma (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. HYBIO (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Glatiramer Sale, by Type, Application, Route of Administration, Intake Form and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Glatiramer (Value)
      • 7.2.1. Global Glatiramer by: Type (Value)
        • 7.2.1.1. Brand Medicine
        • 7.2.1.2. Generic Drug
      • 7.2.2. Global Glatiramer by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Pharmacy
        • 7.2.2.3. Other
      • 7.2.3. Global Glatiramer by: Route of Administration (Value)
        • 7.2.3.1. Enteral Route
        • 7.2.3.2. Parenteral Route
      • 7.2.4. Global Glatiramer by: Intake Form (Value)
        • 7.2.4.1. Alone
        • 7.2.4.2. With Other Medications
      • 7.2.5. Global Glatiramer Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Glatiramer: by Type(USD Million)
  • Table 2. Glatiramer Brand Medicine , by Region USD Million (2018-2023)
  • Table 3. Glatiramer Generic Drug , by Region USD Million (2018-2023)
  • Table 4. Glatiramer: by Application(USD Million)
  • Table 5. Glatiramer Hospital , by Region USD Million (2018-2023)
  • Table 6. Glatiramer Pharmacy , by Region USD Million (2018-2023)
  • Table 7. Glatiramer Other , by Region USD Million (2018-2023)
  • Table 8. Glatiramer: by Route of Administration(USD Million)
  • Table 9. Glatiramer Enteral Route , by Region USD Million (2018-2023)
  • Table 10. Glatiramer Parenteral Route , by Region USD Million (2018-2023)
  • Table 11. Glatiramer: by Intake Form(USD Million)
  • Table 12. Glatiramer Alone , by Region USD Million (2018-2023)
  • Table 13. Glatiramer With Other Medications , by Region USD Million (2018-2023)
  • Table 14. South America Glatiramer, by Country USD Million (2018-2023)
  • Table 15. South America Glatiramer, by Type USD Million (2018-2023)
  • Table 16. South America Glatiramer, by Application USD Million (2018-2023)
  • Table 17. South America Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 18. South America Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 19. Brazil Glatiramer, by Type USD Million (2018-2023)
  • Table 20. Brazil Glatiramer, by Application USD Million (2018-2023)
  • Table 21. Brazil Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 22. Brazil Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 23. Argentina Glatiramer, by Type USD Million (2018-2023)
  • Table 24. Argentina Glatiramer, by Application USD Million (2018-2023)
  • Table 25. Argentina Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 26. Argentina Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 27. Rest of South America Glatiramer, by Type USD Million (2018-2023)
  • Table 28. Rest of South America Glatiramer, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 30. Rest of South America Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 31. Asia Pacific Glatiramer, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Glatiramer, by Type USD Million (2018-2023)
  • Table 33. Asia Pacific Glatiramer, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 35. Asia Pacific Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 36. China Glatiramer, by Type USD Million (2018-2023)
  • Table 37. China Glatiramer, by Application USD Million (2018-2023)
  • Table 38. China Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 39. China Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 40. Japan Glatiramer, by Type USD Million (2018-2023)
  • Table 41. Japan Glatiramer, by Application USD Million (2018-2023)
  • Table 42. Japan Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 43. Japan Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 44. India Glatiramer, by Type USD Million (2018-2023)
  • Table 45. India Glatiramer, by Application USD Million (2018-2023)
  • Table 46. India Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 47. India Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 48. South Korea Glatiramer, by Type USD Million (2018-2023)
  • Table 49. South Korea Glatiramer, by Application USD Million (2018-2023)
  • Table 50. South Korea Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 51. South Korea Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 52. Taiwan Glatiramer, by Type USD Million (2018-2023)
  • Table 53. Taiwan Glatiramer, by Application USD Million (2018-2023)
  • Table 54. Taiwan Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 55. Taiwan Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 56. Australia Glatiramer, by Type USD Million (2018-2023)
  • Table 57. Australia Glatiramer, by Application USD Million (2018-2023)
  • Table 58. Australia Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 59. Australia Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Glatiramer, by Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Glatiramer, by Application USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 64. Europe Glatiramer, by Country USD Million (2018-2023)
  • Table 65. Europe Glatiramer, by Type USD Million (2018-2023)
  • Table 66. Europe Glatiramer, by Application USD Million (2018-2023)
  • Table 67. Europe Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 68. Europe Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 69. Germany Glatiramer, by Type USD Million (2018-2023)
  • Table 70. Germany Glatiramer, by Application USD Million (2018-2023)
  • Table 71. Germany Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 72. Germany Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 73. France Glatiramer, by Type USD Million (2018-2023)
  • Table 74. France Glatiramer, by Application USD Million (2018-2023)
  • Table 75. France Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 76. France Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 77. Italy Glatiramer, by Type USD Million (2018-2023)
  • Table 78. Italy Glatiramer, by Application USD Million (2018-2023)
  • Table 79. Italy Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 80. Italy Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 81. United Kingdom Glatiramer, by Type USD Million (2018-2023)
  • Table 82. United Kingdom Glatiramer, by Application USD Million (2018-2023)
  • Table 83. United Kingdom Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 84. United Kingdom Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 85. Netherlands Glatiramer, by Type USD Million (2018-2023)
  • Table 86. Netherlands Glatiramer, by Application USD Million (2018-2023)
  • Table 87. Netherlands Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 88. Netherlands Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 89. Rest of Europe Glatiramer, by Type USD Million (2018-2023)
  • Table 90. Rest of Europe Glatiramer, by Application USD Million (2018-2023)
  • Table 91. Rest of Europe Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 92. Rest of Europe Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 93. MEA Glatiramer, by Country USD Million (2018-2023)
  • Table 94. MEA Glatiramer, by Type USD Million (2018-2023)
  • Table 95. MEA Glatiramer, by Application USD Million (2018-2023)
  • Table 96. MEA Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 97. MEA Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 98. Middle East Glatiramer, by Type USD Million (2018-2023)
  • Table 99. Middle East Glatiramer, by Application USD Million (2018-2023)
  • Table 100. Middle East Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 101. Middle East Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 102. Africa Glatiramer, by Type USD Million (2018-2023)
  • Table 103. Africa Glatiramer, by Application USD Million (2018-2023)
  • Table 104. Africa Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 105. Africa Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 106. North America Glatiramer, by Country USD Million (2018-2023)
  • Table 107. North America Glatiramer, by Type USD Million (2018-2023)
  • Table 108. North America Glatiramer, by Application USD Million (2018-2023)
  • Table 109. North America Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 110. North America Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 111. United States Glatiramer, by Type USD Million (2018-2023)
  • Table 112. United States Glatiramer, by Application USD Million (2018-2023)
  • Table 113. United States Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 114. United States Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 115. Canada Glatiramer, by Type USD Million (2018-2023)
  • Table 116. Canada Glatiramer, by Application USD Million (2018-2023)
  • Table 117. Canada Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 118. Canada Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 119. Mexico Glatiramer, by Type USD Million (2018-2023)
  • Table 120. Mexico Glatiramer, by Application USD Million (2018-2023)
  • Table 121. Mexico Glatiramer, by Route of Administration USD Million (2018-2023)
  • Table 122. Mexico Glatiramer, by Intake Form USD Million (2018-2023)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Glatiramer: by Type(USD Million)
  • Table 129. Glatiramer Brand Medicine , by Region USD Million (2025-2030)
  • Table 130. Glatiramer Generic Drug , by Region USD Million (2025-2030)
  • Table 131. Glatiramer: by Application(USD Million)
  • Table 132. Glatiramer Hospital , by Region USD Million (2025-2030)
  • Table 133. Glatiramer Pharmacy , by Region USD Million (2025-2030)
  • Table 134. Glatiramer Other , by Region USD Million (2025-2030)
  • Table 135. Glatiramer: by Route of Administration(USD Million)
  • Table 136. Glatiramer Enteral Route , by Region USD Million (2025-2030)
  • Table 137. Glatiramer Parenteral Route , by Region USD Million (2025-2030)
  • Table 138. Glatiramer: by Intake Form(USD Million)
  • Table 139. Glatiramer Alone , by Region USD Million (2025-2030)
  • Table 140. Glatiramer With Other Medications , by Region USD Million (2025-2030)
  • Table 141. South America Glatiramer, by Country USD Million (2025-2030)
  • Table 142. South America Glatiramer, by Type USD Million (2025-2030)
  • Table 143. South America Glatiramer, by Application USD Million (2025-2030)
  • Table 144. South America Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 145. South America Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 146. Brazil Glatiramer, by Type USD Million (2025-2030)
  • Table 147. Brazil Glatiramer, by Application USD Million (2025-2030)
  • Table 148. Brazil Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 149. Brazil Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 150. Argentina Glatiramer, by Type USD Million (2025-2030)
  • Table 151. Argentina Glatiramer, by Application USD Million (2025-2030)
  • Table 152. Argentina Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 153. Argentina Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 154. Rest of South America Glatiramer, by Type USD Million (2025-2030)
  • Table 155. Rest of South America Glatiramer, by Application USD Million (2025-2030)
  • Table 156. Rest of South America Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 157. Rest of South America Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 158. Asia Pacific Glatiramer, by Country USD Million (2025-2030)
  • Table 159. Asia Pacific Glatiramer, by Type USD Million (2025-2030)
  • Table 160. Asia Pacific Glatiramer, by Application USD Million (2025-2030)
  • Table 161. Asia Pacific Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 162. Asia Pacific Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 163. China Glatiramer, by Type USD Million (2025-2030)
  • Table 164. China Glatiramer, by Application USD Million (2025-2030)
  • Table 165. China Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 166. China Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 167. Japan Glatiramer, by Type USD Million (2025-2030)
  • Table 168. Japan Glatiramer, by Application USD Million (2025-2030)
  • Table 169. Japan Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 170. Japan Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 171. India Glatiramer, by Type USD Million (2025-2030)
  • Table 172. India Glatiramer, by Application USD Million (2025-2030)
  • Table 173. India Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 174. India Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 175. South Korea Glatiramer, by Type USD Million (2025-2030)
  • Table 176. South Korea Glatiramer, by Application USD Million (2025-2030)
  • Table 177. South Korea Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 178. South Korea Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 179. Taiwan Glatiramer, by Type USD Million (2025-2030)
  • Table 180. Taiwan Glatiramer, by Application USD Million (2025-2030)
  • Table 181. Taiwan Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 182. Taiwan Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 183. Australia Glatiramer, by Type USD Million (2025-2030)
  • Table 184. Australia Glatiramer, by Application USD Million (2025-2030)
  • Table 185. Australia Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 186. Australia Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 187. Rest of Asia-Pacific Glatiramer, by Type USD Million (2025-2030)
  • Table 188. Rest of Asia-Pacific Glatiramer, by Application USD Million (2025-2030)
  • Table 189. Rest of Asia-Pacific Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 190. Rest of Asia-Pacific Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 191. Europe Glatiramer, by Country USD Million (2025-2030)
  • Table 192. Europe Glatiramer, by Type USD Million (2025-2030)
  • Table 193. Europe Glatiramer, by Application USD Million (2025-2030)
  • Table 194. Europe Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 195. Europe Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 196. Germany Glatiramer, by Type USD Million (2025-2030)
  • Table 197. Germany Glatiramer, by Application USD Million (2025-2030)
  • Table 198. Germany Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 199. Germany Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 200. France Glatiramer, by Type USD Million (2025-2030)
  • Table 201. France Glatiramer, by Application USD Million (2025-2030)
  • Table 202. France Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 203. France Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 204. Italy Glatiramer, by Type USD Million (2025-2030)
  • Table 205. Italy Glatiramer, by Application USD Million (2025-2030)
  • Table 206. Italy Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 207. Italy Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 208. United Kingdom Glatiramer, by Type USD Million (2025-2030)
  • Table 209. United Kingdom Glatiramer, by Application USD Million (2025-2030)
  • Table 210. United Kingdom Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 211. United Kingdom Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 212. Netherlands Glatiramer, by Type USD Million (2025-2030)
  • Table 213. Netherlands Glatiramer, by Application USD Million (2025-2030)
  • Table 214. Netherlands Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 215. Netherlands Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 216. Rest of Europe Glatiramer, by Type USD Million (2025-2030)
  • Table 217. Rest of Europe Glatiramer, by Application USD Million (2025-2030)
  • Table 218. Rest of Europe Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 219. Rest of Europe Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 220. MEA Glatiramer, by Country USD Million (2025-2030)
  • Table 221. MEA Glatiramer, by Type USD Million (2025-2030)
  • Table 222. MEA Glatiramer, by Application USD Million (2025-2030)
  • Table 223. MEA Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 224. MEA Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 225. Middle East Glatiramer, by Type USD Million (2025-2030)
  • Table 226. Middle East Glatiramer, by Application USD Million (2025-2030)
  • Table 227. Middle East Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 228. Middle East Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 229. Africa Glatiramer, by Type USD Million (2025-2030)
  • Table 230. Africa Glatiramer, by Application USD Million (2025-2030)
  • Table 231. Africa Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 232. Africa Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 233. North America Glatiramer, by Country USD Million (2025-2030)
  • Table 234. North America Glatiramer, by Type USD Million (2025-2030)
  • Table 235. North America Glatiramer, by Application USD Million (2025-2030)
  • Table 236. North America Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 237. North America Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 238. United States Glatiramer, by Type USD Million (2025-2030)
  • Table 239. United States Glatiramer, by Application USD Million (2025-2030)
  • Table 240. United States Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 241. United States Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 242. Canada Glatiramer, by Type USD Million (2025-2030)
  • Table 243. Canada Glatiramer, by Application USD Million (2025-2030)
  • Table 244. Canada Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 245. Canada Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 246. Mexico Glatiramer, by Type USD Million (2025-2030)
  • Table 247. Mexico Glatiramer, by Application USD Million (2025-2030)
  • Table 248. Mexico Glatiramer, by Route of Administration USD Million (2025-2030)
  • Table 249. Mexico Glatiramer, by Intake Form USD Million (2025-2030)
  • Table 250. Research Programs/Design for This Report
  • Table 251. Key Data Information from Secondary Sources
  • Table 252. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Glatiramer: by Type USD Million (2018-2023)
  • Figure 5. Global Glatiramer: by Application USD Million (2018-2023)
  • Figure 6. Global Glatiramer: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Glatiramer: by Intake Form USD Million (2018-2023)
  • Figure 8. South America Glatiramer Share (%), by Country
  • Figure 9. Asia Pacific Glatiramer Share (%), by Country
  • Figure 10. Europe Glatiramer Share (%), by Country
  • Figure 11. MEA Glatiramer Share (%), by Country
  • Figure 12. North America Glatiramer Share (%), by Country
  • Figure 13. Global Glatiramer share by Players 2023 (%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 16. Teva (Israel) Revenue: by Geography 2023
  • Figure 17. NATCO Pharma (India) Revenue, Net Income and Gross profit
  • Figure 18. NATCO Pharma (India) Revenue: by Geography 2023
  • Figure 19. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 20. Mylan (United States) Revenue: by Geography 2023
  • Figure 21. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 23. HYBIO (China) Revenue, Net Income and Gross profit
  • Figure 24. HYBIO (China) Revenue: by Geography 2023
  • Figure 25. Global Glatiramer: by Type USD Million (2025-2030)
  • Figure 26. Global Glatiramer: by Application USD Million (2025-2030)
  • Figure 27. Global Glatiramer: by Route of Administration USD Million (2025-2030)
  • Figure 28. Global Glatiramer: by Intake Form USD Million (2025-2030)
  • Figure 29. South America Glatiramer Share (%), by Country
  • Figure 30. Asia Pacific Glatiramer Share (%), by Country
  • Figure 31. Europe Glatiramer Share (%), by Country
  • Figure 32. MEA Glatiramer Share (%), by Country
  • Figure 33. North America Glatiramer Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Teva (Israel)
  • NATCO Pharma (India)
  • Mylan (United States)
  • Novartis (Switzerland)
  • HYBIO (China)
Select User Access Type

Key Highlights of Report


Feb 2024 206 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Glatiramer Market Quantitative research analysis
Global Glatiramer Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Glatiramer Market are by type [Brand Medicine and Generic Drug], by end use application [Hospital, Pharmacy and Other].
The Glatiramer Market is gaining popularity and expected to see strong valuation by 2030.
  • The Growing Geriatric Population Is Expected To Drive Growth Of The Market Over The Forecast Period.

Know More About Global Glatiramer Market Report?

Have a Query? Click Here

Other Related Reports

Metformin Drugs Comprehensive Study by Type (Metformin-Alogliptin, Metformin-Canagliflozin, Metformin-Dapagliflozin, Metformin-Empagliflozin, Others), Category (Immediate Release, Extended Release), ...
$ 3650
Anlotinib Drugs Comprehensive Study by Application (Hospital, Drug Store, Other), Distribution Channel (Online, Offline), End-User (Adult, Paediatric), Strength (8 mg, 10 mg, 12 mg) Players and Regio...
$ 3500
Osimertinib Comprehensive Study by Application (Cancer Clinics, Hospitals, Research Institutions), Distribution Channel (Online, Offline), End-User (Men, Women), Strength (40 mg, 80 mg)
$ 3500
GLP Analogs Comprehensive Study by Drug (Exenatide, Liraglutide, Lixisenatide, Dulaglutide, Semaglutide, Albiglutide), Distribution Channel (Retail Pharmacy, Hospital Pharmacy) Players and Region - G...
$ 3500
Crohn’s Disease Treatment Comprehensive Study by Type (Drug (Anti-inflammatory drugs, Oral 5-aminosalicylates, Biologics, Antibiotics, and Other), Nutrition Therapy, Surgery), Route of Administration...
$ 3450
Parkinson’s Disease Therapeutics Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), Route of Administration (Oral, Parental (Rectal, Intranasa...
$ 3650